The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
This is what it says in the first patient dosed RMS on the 6th June 2023 - "full safety data from this trial are expected to be available during the first half of 2024 and, provided satisfactory results are obtained, a Phase 1b clinical study is expected to commence as soon as possible thereafter in psoriasis patients."
I just saw this on twitter. You can now register on Investor Meet Company to view Scancell investor meetings. They will presumably do their AGM's etc via this so we won't need to rely on private recordings! (Thanks again Botski).
Another sign of a more professional, business orientated approach by the company.
https://twitter.com/InvestorMeetCo/status/1678062432080592898?t=5YuNTUONL03rgQXWOph1WQ&s=19
Scancell's tweet with a link to Lindy's interview.
https://twitter.com/scancellpharma/status/1670751935362727936?t=Ar_HeDKKB3fcwIjQDmVqYw&s=19
Violindog,
"Moditope's not looking too great". To who? Scancell certainly seem happy enough to present the data they have. Prof. Ottensmeier seems happy to present the data. The SP spiked massively on the first news too. Impatience seems to be the issue here.
AB,
Regarding funding, the CEO's words at the AGM were - "The cash runway extends to Q1 2024. We will need to do deals, and further things, to extend beyond that".
That's a slightly different perspective to "obtaining funding".
May have to wait a couple of months if that red dot is about 1801.
"Approval time for clinical trials in Australia
Human Research Ethics Committee (HREC) review takes 1-3 months (however, it depends upon the institution), and CTN review takes about 7–14 days."